See more : ES NETWORKS CO LTD (5867.T) Income Statement Analysis – Financial Results
Complete financial analysis of Jaguar Health, Inc. (JAGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jaguar Health, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Organic Agricultural Company Limited (OGAA) Income Statement Analysis – Financial Results
- Winner Technology Co., Inc. (300609.SZ) Income Statement Analysis – Financial Results
- Maharashtra Scooters Ltd. (MAHSCOOTER.BO) Income Statement Analysis – Financial Results
- Bass Oil Limited (BAS.AX) Income Statement Analysis – Financial Results
- Nila Spaces Limited (NILASPACES.BO) Income Statement Analysis – Financial Results
Jaguar Health, Inc. (JAGX)
About Jaguar Health, Inc.
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.76M | 11.96M | 4.34M | 9.39M | 5.78M | 4.42M | 4.36M | 141.52K | 258.38K | 0.00 |
| Cost of Revenue | 2.04M | 2.02M | 2.33M | 3.28M | 3.82M | 2.77M | 880.41K | 51.97K | 123.46K | 0.00 |
| Gross Profit | 7.72M | 9.94M | 2.00M | 6.11M | 1.96M | 1.65M | 3.48M | 89.56K | 134.92K | 0.00 |
| Gross Profit Ratio | 79.13% | 83.11% | 46.18% | 65.05% | 33.93% | 37.37% | 79.81% | 63.28% | 52.22% | 0.00% |
| Research & Development | 18.60M | 17.65M | 15.08M | 6.41M | 5.82M | 5.15M | 4.27M | 7.21M | 6.48M | 4.22M |
| General & Administrative | 16.59M | 17.87M | 17.10M | 14.39M | 13.50M | 12.28M | 11.25M | 5.98M | 5.34M | 0.00 |
| Selling & Marketing | 6.46M | 8.84M | 8.89M | 6.61M | 6.94M | 9.83M | 3.08M | 485.44K | 765.09K | 0.00 |
| SG&A | 23.05M | 26.71M | 26.00M | 21.00M | 20.44M | 22.11M | 14.33M | 6.47M | 6.10M | 4.10M |
| Other Expenses | 371.00K | 950.00K | -765.00K | 190.00K | 648.80K | 315.69K | 88.55K | -11.05K | -27.28K | 0.00 |
| Operating Expenses | 42.02M | 44.35M | 41.08M | 27.41M | 26.91M | 27.26M | 18.60M | 13.68M | 12.58M | 8.32M |
| Cost & Expenses | 44.05M | 46.37M | 43.41M | 30.69M | 30.72M | 30.03M | 19.48M | 13.73M | 12.70M | 8.32M |
| Interest Income | 0.00 | 12.72M | 8.42M | 2.79M | 5.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.38M | 12.72M | 8.42M | 2.79M | 5.73M | 2.63M | 1.21M | 985.55K | 3.32M | 0.00 |
| Depreciation & Amortization | 1.16M | 2.29M | 1.83M | 2.28M | 1.93M | 1.75M | 584.34K | 47.49K | 5.16K | -51.42K |
| EBITDA | -33.13M | -33.38M | -42.35M | -28.74M | -30.87M | -27.77M | -11.13M | -13.70M | -12.97M | -8.37M |
| EBITDA Ratio | -339.42% | -260.73% | -914.88% | -257.61% | -397.20% | -454.56% | 100.27% | -9,459.45% | -4,620.54% | 0.00% |
| Operating Income | -34.29M | -34.42M | -39.07M | -21.30M | -24.95M | -30.82M | -34.25M | -13.59M | -12.45M | -8.32M |
| Operating Income Ratio | -351.31% | -287.85% | -901.36% | -227.00% | -431.98% | -697.98% | -785.27% | -9,599.84% | -4,816.67% | 0.00% |
| Total Other Income/Expenses | -7.61M | -13.98M | -11.89M | -7.16M | -9.58M | -1.32M | -902.80K | -1.15M | -3.85M | -293.91K |
| Income Before Tax | -41.90M | -48.40M | -52.60M | -33.81M | -38.53M | -32.15M | -35.15M | -14.73M | -16.29M | -8.61M |
| Income Before Tax Ratio | -429.27% | -404.78% | -1,213.38% | -360.25% | -667.15% | -727.92% | -805.97% | -10,410.87% | -6,305.24% | 0.00% |
| Income Tax Expense | 0.00 | -941.00K | 7.65M | 2.98M | 10.00K | -1.28M | -13.18M | 1.14M | 3.82M | 345.34K |
| Net Income | -41.30M | -47.45M | -60.25M | -36.79M | -38.54M | -32.15M | -21.97M | -14.73M | -16.29M | -8.61M |
| Net Income Ratio | -423.11% | -396.91% | -1,389.87% | -392.02% | -667.32% | -727.92% | -503.73% | -10,410.87% | -6,305.24% | 0.00% |
| EPS | -107.42 | -36.18 | -101.07 | -214.22 | -1.75K | -15.51K | -27.26K | -249.73K | -479.16K | -204.99K |
| EPS Diluted | -107.42 | -36.18 | -101.07 | -214.22 | -1.75K | -15.51K | -27.26K | -249.73K | -479.16K | -204.99K |
| Weighted Avg Shares Out | 384.47K | 1.31M | 596.15K | 171.75K | 22.07K | 2.07K | 806.00 | 59.00 | 34.00 | 42.00 |
| Weighted Avg Shares Out (Dil) | 384.47K | 1.31M | 596.15K | 171.75K | 22.07K | 2.07K | 806.00 | 59.00 | 34.00 | 42.00 |
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial's Clinically Meaningful Results in Breast and Lung Cancer Patients
Jaguar to explore approval pathway for crofelemer in breast and lung cancer based on phase 3 results Click here to register for investor webcast Company plans to file its Earnings Report on August 13, 2024 on Form 10-Q for the...
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Dr. Elisabetsky is also an advisor to Magdalena Biosciences , the joint venture formed by Jaguar and Filament Health focused on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions As announced , Jaguar recently...
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of two...
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
New patent issued for core rare disease target indication for crofelemer Jaguar has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome (SBS) and microvillus inclusion...
Why Is Jaguar Health (JAGX) Stock Down 55% Today?
Jaguar Health (NASDAQ: JAGX ) stock is taking a beating on Tuesday after the commercial-stage pharmaceuticals company reported results from a Phase 3 clinical trial. This trial covers the use of crofelemer as a treatment for prophylaxis of diarrhea in adult...
Jaguar Health's stock slides 68% after cancer trial fails to meet main goal
Jaguar Health Inc.'s stock JAGX, +0.23% tumbled 68% early Tuesday, after the biotech said a late-stage trial of a cancer drug failed to meet its main goal across all tumor types. San Francisco-based Jaguar said the Phase 3 trial of...
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory...
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here...
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
JAGX's securities continue to be listed and traded on Nasdaq Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / June 26,...
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation...
Source: https://incomestatements.info
Category: Stock Reports